tiprankstipranks
Blurbs

SVB Securities Reaffirms Their Buy Rating on HilleVax, Inc (HLVX)

SVB Securities analyst David Risinger maintained a Buy rating on HilleVax, Inc (HLVXResearch Report) on November 10 and set a price target of $30.00. The company’s shares closed last Friday at $19.23.

According to TipRanks, Risinger is a 4-star analyst with an average return of 13.1% and a 66.67% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Pfizer, and Eli Lilly & Co.

HilleVax, Inc has an analyst consensus of Moderate Buy, with a price target consensus of $30.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $24.42 and a one-year low of $7.90. Currently, HilleVax, Inc has an average volume of 75.96K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Read More on HLVX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles